[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE476436T1 - Synthese von combretastatin a-4 prodrugs - Google Patents

Synthese von combretastatin a-4 prodrugs

Info

Publication number
ATE476436T1
ATE476436T1 AT99902121T AT99902121T ATE476436T1 AT E476436 T1 ATE476436 T1 AT E476436T1 AT 99902121 T AT99902121 T AT 99902121T AT 99902121 T AT99902121 T AT 99902121T AT E476436 T1 ATE476436 T1 AT E476436T1
Authority
AT
Austria
Prior art keywords
combretastatin
prodrugs
synthesis
water soluble
derivatives
Prior art date
Application number
AT99902121T
Other languages
English (en)
Inventor
George Pettit
Monte Rhodes
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of ATE476436T1 publication Critical patent/ATE476436T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99902121T 1998-01-09 1999-01-08 Synthese von combretastatin a-4 prodrugs ATE476436T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7107098P 1998-01-09 1998-01-09
US11153198P 1998-12-09 1998-12-09
PCT/US1999/000419 WO1999035150A1 (en) 1998-01-09 1999-01-08 Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f

Publications (1)

Publication Number Publication Date
ATE476436T1 true ATE476436T1 (de) 2010-08-15

Family

ID=26751799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902121T ATE476436T1 (de) 1998-01-09 1999-01-08 Synthese von combretastatin a-4 prodrugs

Country Status (7)

Country Link
US (3) US7018987B1 (de)
EP (1) EP1045853B1 (de)
JP (1) JP2002500227A (de)
AT (1) ATE476436T1 (de)
CA (1) CA2314238C (de)
DE (1) DE69942645D1 (de)
WO (1) WO1999035150A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE476436T1 (de) * 1998-01-09 2010-08-15 Univ Arizona Synthese von combretastatin a-4 prodrugs
US6239123B1 (en) 1998-08-11 2001-05-29 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
ES2395097T3 (es) * 2000-04-27 2013-02-08 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona En Nombre De Arizona State University Profármacos de Combretastatina A1 fosfato y Combretastatina B1 fosfato
US6743937B2 (en) 2000-07-17 2004-06-01 Oxigene, Inc. Efficient method of synthesizing combretastatin A-4 prodrugs
GB0019944D0 (en) * 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
EP1559718A1 (de) * 2000-09-14 2005-08-03 Bristol-Myers Squibb Company Combretastatine A-4 Phosphate Prodrug Salze mit Stickstoff-enthaltenden Verbindungen
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
CA2432640A1 (en) 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
WO2002056692A1 (en) 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US6773702B2 (en) 2000-12-26 2004-08-10 Oxigene, Inc. Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
US7547686B2 (en) 2001-06-15 2009-06-16 Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University Combretastatin A-3 prodrug
NZ575466A (en) * 2001-07-13 2011-01-28 Oxigene Inc Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003035008A2 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
US7105695B2 (en) 2001-12-21 2006-09-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of combretastatin A-2 prodrugs
US20040127467A1 (en) * 2002-04-17 2004-07-01 Pettit George R Synthesis of pancratistatin prodrugs
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
CA2624533A1 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
CN101085743B (zh) * 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
AU2008326251B2 (en) * 2007-11-21 2014-03-06 Mateon Therapeutics, Inc. Method for treating hematopoietic neoplasms
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5484799A (en) * 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
ATE476436T1 (de) * 1998-01-09 2010-08-15 Univ Arizona Synthese von combretastatin a-4 prodrugs

Also Published As

Publication number Publication date
US7279466B2 (en) 2007-10-09
EP1045853B1 (de) 2010-08-04
CA2314238A1 (en) 1999-07-15
EP1045853A1 (de) 2000-10-25
DE69942645D1 (en) 2010-09-16
US20070073077A1 (en) 2007-03-29
WO1999035150A1 (en) 1999-07-15
EP1045853A4 (de) 2002-04-17
CA2314238C (en) 2008-09-02
US7557096B2 (en) 2009-07-07
US7018987B1 (en) 2006-03-28
JP2002500227A (ja) 2002-01-08
US20080146528A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE476436T1 (de) Synthese von combretastatin a-4 prodrugs
ATE270817T1 (de) Fungizide
ATE306261T1 (de) Antithrombosemittel
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
DK1224159T3 (da) Forbedret syntese af racemisk sertralin
TNSN00200A1 (fr) Derives d'ethers de biaryle nouveaux, compositions les contenant et leur utilisation
DE69830504D1 (de) Antithrombotische mitteln
GT199900040A (es) Biciclo [2.2.1] heptanos y compuestos relacionados.
PL309197A1 (en) Novel compositions based on taxoides
PT831837E (pt) Utilizacao de esqualamina no fabrico de um medicamento para inibicao de nhe
PT94085A (pt) Processo para a preparacao de derivados de amino-fenol anti-inflamatorios
ES2097174T3 (es) Derivados de la 2-ciclohexan-1-il amina.
ATE288900T1 (de) Substituierte benzoylcyclohexandione
DK1255747T3 (da) Syntese af 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-on
DE60031886D1 (de) Purinderivate
YU38401A (sh) Derivati benzofurana, njihova izrada i upotreba
ATE257831T1 (de) Synthese von wasserlöslischem 9-dihydroplacitaxel derivate aus 9-dihydro-13-acetylbacchatin iii
IT1318547B1 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.
HRP20000609B1 (en) Process for the synthesis of hiv protease inhibitors
DE59910585D1 (en) 3,4-dihydrochinolin-derivative als stickstoffmonoxid-synthase (nos) inhibitoren
NO983285L (no) Pyrido-1,2,4-tiadiazin- og pyrido-1,4-tiazinderivater, deres fremstilling og anvendelse
FR2437405A1 (fr) Nouveaux alcoylbenzenes substitues basiques utiles comme medicaments
ID27440A (id) Proses untuk menyiapkan penengah-penengah
IT1277339B1 (it) Processo per la produzione di agenti contrastografici iodurati
BG105646A (en) Benzofuran derivatives, their preparation and use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties